Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:CMRX's Cash-to-Debt is ranked higher than
77% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. NAS:CMRX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CMRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.64  Med: 174.08 Max: No Debt
Current: No Debt
1.64
No Debt
Equity-to-Asset 0.96
NAS:CMRX's Equity-to-Asset is ranked higher than
94% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:CMRX: 0.96 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CMRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.14  Med: 0.94 Max: 0.97
Current: 0.96
-5.14
0.97
Interest Coverage No Debt
NAS:CMRX's Interest Coverage is ranked higher than
71% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:CMRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:CMRX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 11.21
Beneish M-Score: -3.74
WACC vs ROIC
15.33%
-91.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -1762.93
NAS:CMRX's Operating Margin % is ranked lower than
81% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. NAS:CMRX: -1762.93 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CMRX' s Operating Margin % Range Over the Past 10 Years
Min: -1762.93  Med: -1232.94 Max: -8.25
Current: -1762.93
-1762.93
-8.25
Net Margin % -1736.95
NAS:CMRX's Net Margin % is ranked lower than
81% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. NAS:CMRX: -1736.95 )
Ranked among companies with meaningful Net Margin % only.
NAS:CMRX' s Net Margin % Range Over the Past 10 Years
Min: -1736.95  Med: -1215.17 Max: -13.07
Current: -1736.95
-1736.95
-13.07
ROE % -31.02
NAS:CMRX's ROE % is ranked higher than
57% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. NAS:CMRX: -31.02 )
Ranked among companies with meaningful ROE % only.
NAS:CMRX' s ROE % Range Over the Past 10 Years
Min: -38.48  Med: -30.15 Max: -24.98
Current: -31.02
-38.48
-24.98
ROA % -29.79
NAS:CMRX's ROA % is ranked higher than
54% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. NAS:CMRX: -29.79 )
Ranked among companies with meaningful ROA % only.
NAS:CMRX' s ROA % Range Over the Past 10 Years
Min: -201.23  Med: -29.27 Max: -15.34
Current: -29.79
-201.23
-15.34
ROC (Joel Greenblatt) % -3531.24
NAS:CMRX's ROC (Joel Greenblatt) % is ranked lower than
76% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. NAS:CMRX: -3531.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CMRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8909.8  Med: -5430.59 Max: -575
Current: -3531.24
-8909.8
-575
3-Year Revenue Growth Rate -7.70
NAS:CMRX's 3-Year Revenue Growth Rate is ranked lower than
64% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. NAS:CMRX: -7.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CMRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -59.2 Max: -7.7
Current: -7.7
3-Year EBITDA Growth Rate 5.20
NAS:CMRX's 3-Year EBITDA Growth Rate is ranked higher than
53% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. NAS:CMRX: 5.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CMRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -4.2 Max: 52.5
Current: 5.2
0
52.5
3-Year EPS without NRI Growth Rate 5.70
NAS:CMRX's 3-Year EPS without NRI Growth Rate is ranked higher than
53% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NAS:CMRX: 5.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CMRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.7 Max: 57.5
Current: 5.7
0
57.5
GuruFocus has detected 3 Warning Signs with Chimerix Inc NAS:CMRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CMRX's 30-Y Financials

Financials (Next Earnings Date: 2018-08-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

CMRX Guru Trades in Q2 2017

Paul Tudor Jones 36,640 sh (-8.06%)
Jim Simons 42,960 sh (-86.12%)
» More
Q3 2017

CMRX Guru Trades in Q3 2017

Jim Simons 193,960 sh (+351.49%)
Paul Tudor Jones 38,629 sh (+5.43%)
» More
Q4 2017

CMRX Guru Trades in Q4 2017

Jim Simons 259,152 sh (+33.61%)
Paul Tudor Jones 25,723 sh (-33.41%)
» More
Q1 2018

CMRX Guru Trades in Q1 2018

Pioneer Investments 16,300 sh (New)
Jim Simons 347,621 sh (+34.14%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:CMRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Chimerix Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:FBIO, NAS:CALA, NAS:BLCM, NAS:OCUL, ASX:PNV, NAS:CDXC, AMEX:AMPE, OTCPK:AXIM, NAS:NERV, NAS:ATHX, OTCPK:ELOX, NAS:CASI, ROCO:6575, NAS:MTEM, MIL:MLM, NAS:VTL, NAS:ARDX, BOM:531349, LSE:IMM, NAS:AVDL » details
Traded in other countries:CXF.Germany,
Headquarter Location:USA
Chimerix Inc is a biopharmaceutical company which focuses on the discovery, development, and commercialization of novel, oral antivirals in areas of unmet medical needs.

Chimerix Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel, oral antivirals in areas of unmet medical needs. The company's research is based on its proprietary lipid conjugate technology's ability to enhance antiviral activity of the broad-spectrum antivirals. The company's focus is on novel nucleosides with activity against influenza, norovirus, CMV, and BK virus, among others. It derives its revenue from two sources contracts and grants, and collaborations and licensing.

Top Ranked Articles about Chimerix Inc

New Research: Key Drivers of Growth for Webster Financial, Chimerix, Commerce Bancshares, Teligent, Pinnacle Financial Partners, and Empire State Realty Trust — Factors of Influence, Major Initiatives and Sustained Production
Chimerix Announces Discovery and Demonstrated Preclinical Activity Supporting Ongoing Phase 1 Study of New Antiviral for Treatment and Prevention of Norovirus
Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox
Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)
Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)
Recent Analysis Shows Camden Property Trust, Biglari, Argan, Chimerix, Workhorse Group, and Magellan Midstream Partners Market Influences — Renewed Outlook, Key Drivers of Growth
Chimerix Announces First Quarter 2018 Financial Results
Chimerix to Present at the Deutsche Bank 43rd Annual Health Care Conference
Chimerix to Announce First Quarter 2018 Financial Results on May 7, 2018
Chimerix to Present at the H.C. Wainwright Annual Global Life Sciences Conference

Ratios

vs
industry
vs
history
PB Ratio 1.06
CMRX's PB Ratio is ranked higher than
90% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. CMRX: 1.06 )
Ranked among companies with meaningful PB Ratio only.
CMRX' s PB Ratio Range Over the Past 10 Years
Min: 0.57  Med: 3.66 Max: 8.16
Current: 1.06
0.57
8.16
PS Ratio 51.79
CMRX's PS Ratio is ranked lower than
77% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CMRX: 51.79 )
Ranked among companies with meaningful PS Ratio only.
CMRX' s PS Ratio Range Over the Past 10 Years
Min: 8.02  Med: 51.57 Max: 348.7
Current: 51.79
8.02
348.7
EV-to-EBIT -0.79
CMRX's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. CMRX: -0.79 )
Ranked among companies with meaningful EV-to-EBIT only.
CMRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -66.2  Med: -9.55 Max: 0.9
Current: -0.79
-66.2
0.9
EV-to-EBITDA -0.80
CMRX's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. CMRX: -0.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
CMRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -68.9  Med: -9.6 Max: 0.9
Current: -0.8
-68.9
0.9
EV-to-Revenue 14.21
CMRX's EV-to-Revenue is ranked lower than
62% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. CMRX: 14.21 )
Ranked among companies with meaningful EV-to-Revenue only.
CMRX' s EV-to-Revenue Range Over the Past 10 Years
Min: -11.9  Med: 21.9 Max: 354.9
Current: 14.21
-11.9
354.9
Current Ratio 18.21
CMRX's Current Ratio is ranked higher than
85% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. CMRX: 18.21 )
Ranked among companies with meaningful Current Ratio only.
CMRX' s Current Ratio Range Over the Past 10 Years
Min: 2.6  Med: 13.36 Max: 26.45
Current: 18.21
2.6
26.45
Quick Ratio 18.21
CMRX's Quick Ratio is ranked higher than
85% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. CMRX: 18.21 )
Ranked among companies with meaningful Quick Ratio only.
CMRX' s Quick Ratio Range Over the Past 10 Years
Min: 2.6  Med: 13.36 Max: 26.45
Current: 18.21
2.6
26.45
Days Sales Outstanding 36.97
CMRX's Days Sales Outstanding is ranked lower than
85% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. CMRX: 36.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
CMRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.48  Med: 82.48 Max: 136.61
Current: 36.97
8.48
136.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.00
CMRX's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CMRX: -5.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CMRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -201.6  Med: -20.4 Max: 0
Current: -5
-201.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.45
CMRX's Price-to-Net-Cash is ranked higher than
92% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. CMRX: 1.45 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CMRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.69  Med: 3.12 Max: 9.87
Current: 1.45
0.69
9.87
Price-to-Net-Current-Asset-Value 1.42
CMRX's Price-to-Net-Current-Asset-Value is ranked higher than
92% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. CMRX: 1.42 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CMRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.68  Med: 3.04 Max: 9.69
Current: 1.42
0.68
9.69
Price-to-Tangible-Book 1.07
CMRX's Price-to-Tangible-Book is ranked higher than
93% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. CMRX: 1.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CMRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.61  Med: 2.65 Max: 6.86
Current: 1.07
0.61
6.86
Price-to-Median-PS-Value 1.00
CMRX's Price-to-Median-PS-Value is ranked lower than
60% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. CMRX: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CMRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1.03 Max: 6.41
Current: 1
0.23
6.41
Earnings Yield (Greenblatt) % -124.07
CMRX's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. CMRX: -124.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CMRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1555.6  Med: -7.1 Max: 4961.7
Current: -124.07
-1555.6
4961.7

More Statistics

Revenue (TTM) (Mil) $4.21
EPS (TTM) $ -1.56
Beta2.08
Volatility24.50%
52-Week Range $4.17 - 5.94
Shares Outstanding (Mil)47.75

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 3 3 23
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -1.73 -2.00 -2.04
EPS without NRI ($) -1.73 -2.00 -2.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}